Quantcast
Last updated on April 17, 2014 at 14:57 EDT

Latest Overactive bladder Stories

2013-05-10 08:24:21

OAB patients treated with Urgent® PC over 36 months sustained their urinary symptom improvement MINNEAPOLIS, May 10, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted the 3-year results of the STEP Study on percutaneous tibial nerve stimulation (PTNS) treatments for overactive bladder (OAB) using Uroplasty's Urgent(®)...

2013-05-07 20:23:52

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that results of three studies of MYRBETRIQ(®) (mirabegron) as a treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency were presented in poster sessions at the American Urological Association Annual (AUA) Meeting in San Diego. The first two studies demonstrated the...

2013-04-10 08:31:06

Myrbetriq is now available in pharmacies across Canada MARKHAM, ON, April 10, 2013 /CNW/ - Overactive bladder (OAB) is a chronic, debilitating condition that can have a profound, negative impact on a patient's quality of life.( 1) Many patients with OAB are plagued by depression,(2) experience a disruption in sleep,(3) limit their social activity,(4) and experience a loss of control and decreased self-esteem.(5) An estimated 2.9 million Canadian men and women(6) suffer from OAB...

2013-03-18 12:29:20

MOUNTAIN VIEW, Calif., March 18, 2013 /PRNewswire/ -- TheraVida, Inc., a clinical-stage biopharmaceutical company developing novel combination drug products, presented positive results from a Phase 2 clinical trial of its lead product candidate, Tolenix((TM)) (THVD-201), for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) at the 28(th) Annual Congress of the European Urological Association (EAU) in Milan, Italy. Tolenix((TM)) is a twice-daily (BID)...

2013-03-14 23:02:07

In 2011, the FDA approved Botox to be utilized for bladder control purposes. After thorough investigation, Women´s Excellence in Bladder Control has made the decision to offer this unique therapy to their patients suffering with urinary incontinence and bladder spasm issues. Greater Metro Detroit, MI (PRWEB) March 14, 2013 Botulinum toxin, otherwise known as Botox, has been historically used by the plastic surgery community to help alleviate wrinkles on the face. Botox relaxes muscular...

2013-03-08 08:23:03

MARKHAM, ON, March 8, 2013 /CNW/ - Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma Inc., announced today Health Canada's approval of Myrbetriq(TM) (mirabegron, extended-release tablets). Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency.(1 )Mirabegron, a selective b3-adrenoceptor agonist, is a "first in class" therapeutic agent with a mechanism of action...

2013-03-07 08:29:02

MINNEAPOLIS, March 7, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Darin Hammers, Vice President of US Sales, will present the Company's business strategy and financial results at the 25th Annual ROTH Growth Stock Conference at 8:30 AM PT on Monday, March 18, 2013 at The Ritz Carlton in Dana Point, CA....

2013-02-28 23:00:09

TheraCoat has developed a new proprietary drug delivery system for local treatment of bladder diseases, focusing currently on bladder cancer and overactive bladder. (PRWEB) February 28, 2013 TheraCoat has developed a new proprietary drug delivery system for local treatment of bladder diseases, focusing currently on bladder cancer and overactive bladder. The novel hydrogel-based system enables controlled and longer exposure of bladder tissue to therapeutic agents as compared to standard...

2013-02-25 16:26:39

MINNEAPOLIS, Feb. 25, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced there will be several presentations on the office-based Urgent PC Neuromodulation System at professional society meetings in February and March 2013. Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), February 27 -March 2, 2013 in...

2013-02-20 23:04:00

Medications that treat overactive bladder (OAB) have notorious side effects such as dry mouth, constipation, and urinary retention. Women´s Excellence in Bladder Control is now trialing and sampling a brand new medication that treats OAB differently. Shelby Township, Michigan (PRWEB) February 20, 2013 Medications that treat overactive bladder (OAB) fall under a class of drugs called “anticholinergics”. Anticholinergic drugs are antispasmodic agents that inhibit the action...